4
Participants
Start Date
November 13, 2017
Primary Completion Date
September 15, 2022
Study Completion Date
September 15, 2022
Hyperpolarized 13C-Pyruvate
The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
18F-FDG
18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
Sunnybrook Health Sciences Centre, Toronto
Collaborators (1)
Ontario Institute for Cancer Research
OTHER
Sunnybrook Health Sciences Centre
OTHER